# Use of Oxandrolone to Promote Growth in Infants With HLHS

> **NCT04090697** · PHASE1,PHASE2 · TERMINATED · sponsor: **Carelon Research** · enrollment: 34 (actual)

## Conditions studied

- Hypoplastic Left Heart
- Congenital Heart Disease

## Interventions

- **DRUG:** Oxandrolone

## Key facts

- **NCT ID:** NCT04090697
- **Lead sponsor:** Carelon Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-20
- **Primary completion:** 2023-09-19
- **Final completion:** 2023-09-19
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** FDA withdrawal of Oxandrin NDA and generic ANDAs
- **Last updated:** 2024-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04090697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04090697, "Use of Oxandrolone to Promote Growth in Infants With HLHS". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04090697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*